Podcast episode 14 (in German)
Tirzepatide (Mounjaro & Zepbound): The strongest approved fat burner fact-checked
July 12, 2026
Tirzepatide works 2 hormone switches at once, GLP-1 and GIP, and achieves around 22 percent lower body weight in the large approval trial. That makes it the strongest approved weight-loss drug, as of July 2026, and behind it lies a small puzzle about the hormone GIP.
What it is about
GLP-1 and GIP are gut hormones of the incretin family; both are released after eating and regulate satiety, insulin and fat metabolism. Tirzepatide is a dual agonist that serves both in one molecule, hence the nickname twincretin. The episode goes through the major trials, from weight to the head-to-head comparison with semaglutide to sleep apnea, and explains why GIP of all things helps, a hormone long regarded as promoting fat storage. It also covers side effects, protecting muscle mass and the question of what happens after stopping. The conclusion is a prescription-only, well-studied medicine from Eli Lilly, marketed as Mounjaro and Zepbound, that amplifies a healthy lifestyle but does not replace it.
Key points
- In SURMOUNT-1, published in the New England Journal of Medicine in 2022, participants on the highest dose lost around 22 percent of their body weight on average over a good 1.5 years.
- For context, the episode cites around 15 percent weight loss for semaglutide and 20 to 22 percent for tirzepatide.
- In the head-to-head comparison in type 2 diabetes, the SURPASS-2 trial, tirzepatide lowered long-term blood sugar more than semaglutide, and participants lost more weight.
- Under the name Zepbound, tirzepatide is also approved for treating obstructive sleep apnea in people with overweight, as of July 2026: less weight, more open airways.
- GIP was long regarded as a hormone that promotes fat storage; in combination with GLP-1 it appears to have a favorable effect on satiety and fat metabolism and to ease nausea somewhat.
- Anecdotal report: many users describe the constant circling of thoughts around food growing quieter, some even more markedly than on semaglutide.
- Tirzepatide is injected under the skin once a week, with a slowly increasing dose; side effects mainly affect the stomach and gut, especially at the start.
Where the data stop
The big numbers apply to the tested product under medical supervision. With such strong weight loss, muscle mass is lost too; plenty of protein and strength training steer the loss toward fat. After stopping, part of the weight often returns because appetite comes back, which is why treatment is increasingly thought of as long-term. Compared with semaglutide, long-term experience is shorter.
The episode does not cite proven heart protection for tirzepatide, as the SELECT trial showed for semaglutide; it refers to large cardiovascular trials. The even stronger retatrutide with 3 targets is not approved, as of July 2026. And none of these numbers apply to copied or adulterated versions circulating online.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on July 12, 2026.
The topic in the database
- The strongest approved fat burner at present: the dual combination of GLP-1 and GIP delivers up to 22.5% weight loss – and beat semaglutide in a direct…Tirzepatide (Mounjaro / Zepbound)
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-09.